Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naval Daver

Showing results (241-250 of 436) with videos related to

Pageof 44
Sort By:
American Journal of Hematology|August 18, 2018
P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse-free survivalRita Assi, Hatice D Gur, Sanam Loghavi, et al.
Communications Biology|July 21, 2023
Single-cell chromatin accessibility profiling of acute myeloid leukemia reveals heterogeneous lineage composition upon therapy-resistanceHuihui Fan, Feng Wang, Andy Zeng, et al.
Leukemia|September 23, 2022
Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1Warren Fiskus, Naval Daver, Steffen Boettcher, et al.
Leukemia Research|November 9, 2015
Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomesTalha Badar, Keyur P Patel, Philip A Thompson, et al.
Acta Haematologica|June 19, 2022
A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating MutationsSai Prasad Desikan, Farhad Ravandi, Naveen Pemmaraju, et al.
Leukemia|May 18, 2018
Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategiesPhilip A Thompson, Christine B Peterson, Paolo Strati, et al.
Leukemia|June 21, 2020
The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemiaMansour Alfayez, Ghayas C Issa, Keyur P Patel, et al.
American Journal of Hematology|August 5, 2021
Development of TP53 mutations over the course of therapy for acute myeloid leukemiaYasmin Alwash, Joseph D Khoury, Mehrnoosh Tashakori, et al.
Cancer|October 15, 2016
Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agentsElias Jabbour, Stefan Faderl, Koji Sasaki, et al.
Leukemia Research|April 19, 2025
Safety and efficacy of the combination of azacitidine with venetoclax after hypomethylating agent failure in higher-risk myelodysplastic syndromeJulie S Braish, Guillermo Montalban-Bravo, Farhad Ravandi, et al.
Pageof 44

Showing results (241-250 of 436) with videos related to

Sort By:
Pageof 44
American Journal of Hematology|August 18, 2018
P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse-free survivalRita Assi, Hatice D Gur, Sanam Loghavi, et al.
Communications Biology|July 21, 2023
Single-cell chromatin accessibility profiling of acute myeloid leukemia reveals heterogeneous lineage composition upon therapy-resistanceHuihui Fan, Feng Wang, Andy Zeng, et al.
Leukemia|September 23, 2022
Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1Warren Fiskus, Naval Daver, Steffen Boettcher, et al.
Leukemia Research|November 9, 2015
Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomesTalha Badar, Keyur P Patel, Philip A Thompson, et al.
Acta Haematologica|June 19, 2022
A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating MutationsSai Prasad Desikan, Farhad Ravandi, Naveen Pemmaraju, et al.
Leukemia|May 18, 2018
Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategiesPhilip A Thompson, Christine B Peterson, Paolo Strati, et al.
Leukemia|June 21, 2020
The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemiaMansour Alfayez, Ghayas C Issa, Keyur P Patel, et al.
American Journal of Hematology|August 5, 2021
Development of TP53 mutations over the course of therapy for acute myeloid leukemiaYasmin Alwash, Joseph D Khoury, Mehrnoosh Tashakori, et al.
Cancer|October 15, 2016
Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agentsElias Jabbour, Stefan Faderl, Koji Sasaki, et al.
Leukemia Research|April 19, 2025
Safety and efficacy of the combination of azacitidine with venetoclax after hypomethylating agent failure in higher-risk myelodysplastic syndromeJulie S Braish, Guillermo Montalban-Bravo, Farhad Ravandi, et al.
Pageof 44